Who are LeonaBio, Inc.'s main suppliers?

LeonaBio, Inc. (LONA) key suppliers include: SERMONIX, SERMONIX-PHARMACEUTICALS-INC, SHANGHAI-HENLIUS-BIOTECH-INC, Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated and 1 more. View the full supplier network at chainsifter.com/chain/LONA.

Who are LeonaBio, Inc.'s major customers?

LeonaBio, Inc. (LONA) key customers include: Ligand Pharmaceuticals Incorporated, Ligand Pharmaceuticals Incorporated, COMMODORE-TCGX-CROSSOVER-MANAGEMENT-LLC, CRO-INOTIV-INC, DELAWARE-GENERAL-CORPORATION and 2 more. View the full customer network at chainsifter.com/chain/LONA.

What sector is LeonaBio, Inc. in?

LeonaBio, Inc. (LONA) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

LeonaBio, Inc. Supplier List (LONA): 6 Verified Suppliers

6Suppliers

7Customers

3Debt Items

17Related Chains

Source-Backed Evidence Depth

LeonaBio, Inc. (LONA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

17Total relationships

4Distinct source URLs

10High confidence

0.777Average confidence

2026-09-13Latest database update

ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

LeonaBio, Inc. Suppliers

Ticker	Name	Confidence	Evidence
SERMONIX	SERMONIX	92%	As consideration for the rights granted to the Company under the Sermonix License Agreement entered into between the Company and Sermonix on December 18, 2025, the Company issued to Sermonix the Serm…
SERMONIX-PHARMACEUTICALS-INC	SERMONIX-PHARMACEUTICALS-INC	90%	Sermonix disclosed to the Company that it incurred aggregate cash expenditures in conducting the ELAINE-3 Study of approximately $14 million, $12 million and $5 million in each of 2023, 2024 and 2025…
SHANGHAI-HENLIUS-BIOTECH-INC	SHANGHAI-HENLIUS-BIOTECH-INC	85%	the Company is coordinating with Sermonix and Shanghai Henlius Biotech, Inc. (“ Henlius ”), Sermonix’s exclusive licensee for oral lasofoxifene in Asia and certain countries in the Middle East
LGND	Ligand Pharmaceuticals Incorporated	80%	Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: Reciprocal relationship from LGND g…
LGND	Ligand Pharmaceuticals Incorporated	80%	granting the Company exclusive licenses and rights to develop, manufacture and commercialize oral forms of the selective estrogen-receptor modulator known as lasofoxifene
LIGAND	LIGAND	80%	we entered into a direct license agreement with Ligand (the "Ligand Agreement") to replace Sermonix's license from Ligand

LeonaBio, Inc. Customers

Ticker	Name	Confidence	Evidence
LGND	Ligand Pharmaceuticals Incorporated	72%	an adequate number of suitable patients to participate in a clinical trial on a timely basis; • the number of patients required for clinical trials of our drug candidates may be larger than we antici…
LGND	Ligand Pharmaceuticals Incorporated	72%	Reciprocal relationship from LGND graph: Reciprocal relationship from LONA graph: an adequate number of suitable patients to participate in a clinical trial on a timely basis; • the number of patient…
COMMODORE-TCGX-CROSSOVER-MANAGEMENT-LLC	COMMODORE-TCGX-CROSSOVER-MANAGEMENT-LLC	62%	million for the three months ended March 31, 2026. The increase was driven primarily by increases in lasofoxifene program costs of $8.6 million and offset by decreases in fosgonimeton program costs o…
CRO-INOTIV-INC	CRO-INOTIV-INC	62%	failures or breaches of our systems or those used by our CROs or other contractors or consultants. We are dependent upon our own or third-party information technology systems, infrastructure and data…
DELAWARE-GENERAL-CORPORATION	DELAWARE-GENERAL-CORPORATION	62%	alties that could adversely affect our business, financial condition or operating results or result in harm to our reputation and brand, sanctions, consent decrees, injunctions or other remedies requ…
SERMONIX-PHARMACEUTICALS-INC	SERMONIX-PHARMACEUTICALS-INC	62%	an adequate number of suitable patients to participate in a clinical trial on a timely basis; • the number of patients required for clinical trials of our drug candidates may be larger than we antici…
WASHINGTON-BUSINESS-CORPORATION	WASHINGTON-BUSINESS-CORPORATION	62%	failures or breaches of our systems or those used by our CROs or other contractors or consultants. We are dependent upon our own or third-party information technology systems, infrastructure and data…

LeonaBio, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
LONA-DEBT	Debt stack $691,000	90%	Market cache reports total debt of $691,000.
LONA-DEBT-10762	Warrants outstanding: 4579000	90%	xbrl warrant detail from xbrl 2025-12-31.
LONA-DEBT-10763	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2020-12-31.

LeonaBio, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for LeonaBio, Inc..

LeonaBio, Inc. Ownership

Holder	Name	Confidence	Evidence
LONA-OWNER-PERCEPTIVE-ADVISORS-LLC	PERCEPTIVE ADVISORS LLC	90%	13F overlay lists PERCEPTIVE ADVISORS LLC as top holder; 40 tracked holders.

LeonaBio, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
OVID	Ovid Therapeutics Inc.	100.00	2
ELUT	Elutia Inc.	100.00	2
VKTX	Viking Therapeutics, Inc.	100.00	2
SGMO	Sangamo Therapeutics, Inc.	100.00	2
PLX	Protalix BioTherapeutics, Inc.	100.00	2
OBIO	Orchestra BioMed Holdings, Inc.	100.00	2
CRMD	CorMedix Inc.	100.00	2
AGEN	Agenus Inc.	100.00	2
OABIW	OmniAb, Inc.	50.00	2
XOMA	XOMA Royalty Corporation	50.00	2
DNTH	Dianthus Therapeutics, Inc.	50.00	2
XOMAP	XOMA Royalty Corporation	50.00	2
LGND	Ligand Pharmaceuticals Incorporated	38.88	1	['customer', 'supplier']
RYLAZE	RYLAZE	23.09	2
LLY	Eli Lilly and Company	14.78	2
PVLA	Palvella Therapeutics, Inc.	14.78	2
SNYNF	Sanofi	14.78	2

LeonaBio, Inc. Supply Chain